ANTAZOLINE

Details

Stereochemistry	ACHIRAL
Molecular Formula	C17H19N3
Molecular Weight	265.3529
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

C(N(CC1=CC=CC=C1)C2=CC=CC=C2)C3=NCCN3

InChI

InChIKey=REYFJDPCWQRWAA-UHFFFAOYSA-N

InChI=1S/C17H19N3/c1-3-7-15(8-4-1)13-20(14-17-18-11-12-19-17)16-9-5-2-6-10-16/h1-10H,11-14H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula	C17H19N3
Molecular Weight	265.3529
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description

Antazoline is an antagonist of histamine H1 receptors. It selectively bind to but does not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine, which subsequently leads to temporary relief of the negative symptoms brought on by histamine. Antazoline in combination with naphazoline (VASOCON-A®) is indicated to relieve the symptoms of allergic conjunctivitis.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Histamine H1 receptor 315	Antagonist 2,778		38.4 nM [Ki]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Allergic conjunctivitis 100	Palliative		Approved 8,429	VASOCON-A

C_max

Value	Dose	Co-administered	Analyte	Population
2.02 mg/L	100 mg single, intravenous		ANTAZOLINE plasma	Homo sapiens

AUC

Value	Dose	Co-administered	Analyte	Population
0.91 mg × h/L	100 mg single, intravenous		ANTAZOLINE plasma	Homo sapiens

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.29 h	100 mg single, intravenous		ANTAZOLINE plasma	Homo sapiens

Doses

Doses

Show entries

Dose	Population	Adverse events
2 drop single, ophthalmic Recommended	healthy, ADULT
250 mg 1 times / 5 min multiple, intravenous Studied dose	unhealthy, ADULT

Showing 1 to 2 of 2 entries

Previous1Next

PubMed

Show entries

Title	Date	PubMed
Interactions of ligands at angiotensin II-receptors and imidazoline receptors.	2001 Feb	11286399
Pharmacometric analysis of alpha1-adrenoceptor function in rat tail artery pretreated with lipopolysaccharides.	2001 Nov-Dec	11985334
Inhibition of voltage-gated Ca2+ channels by antazoline.	2002 Oct 7	12395109
Neuroprotective activity of antazoline against neuronal damage induced by limbic status epilepticus.	2003	12890517
Conjunctival allergen challenge: models in the investigation of ocular allergy.	2003 Jul	12791217

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Patents

Sample Use Guides

In Vivo Use Guide

1-2 drops up to 4 times daily.

Route of Administration: Other

In Vitro Use Guide

The antihistaminic agent, antazoline, was tested for its ability to compete for [3H]pyrilamine, [3H]tiotidine and [3H]N-methyl histamine binding to rodent brain H1, H2 and H3 histamine receptors, respectively. Antazoline exhibited the highest affinity for H1-receptors (dissociation constant, Ki = 38.4 +/- 4.4 nM), and was considerably weaker at H2- (K1 = 44,433 +/- 1,763 nM) and H3-receptors (Ki = 42,400 +/- 7,527 nM).